Treatment for juvenile diabetes
US6288301A · kind A · utility
10Cited by
2References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 30, 1998 |
| Grant date | Sep 11, 2001 |
| Priority date | — |
| Expiry date | Jul 30, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/495
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF.alpha., in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF.alpha. gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.